Natalie Godbee

Molecular sub group and post immunotherapy analysis: Results from NRG GY012

Helen MacKay, B.J. Rimel, David Bender, Shannon Westin et autres

ca, us (code pays fourni par la source)

1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer

Bobbie J. Rimmel, David Andrew Bender, Danielle M. Enserro, Shannon Neville Westin et autres

us, it, ca (code pays fourni par la source)

#430 DB-1303, a HER2-targeting ADC, for patients with advanced/metastatic endometrial cancer: preliminary clinical results from an ongoing phase 1/2a trial (NCT05150691)

Kathleen N. Moore, Vicky Makker, Oladapo Yeku, Bhavana Pothuri et autres

us, cn (code pays fourni par la source)

37 Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race

Ruchi Garg, Julian C. Schink, Barbara M. Buttin, Julia Andrea Elvin et autres

Individualizing oncologic treatment by using precision oncology techniques that allow for detection of genomic alterations (GA) has become critical. We present an analysis of comprehensive genomic profiling (CGP) of a large series of high grade serous ovarian carcinoma (HGSOC) patients assayed in …

us (code pays fourni par la source)

36 Mutational landscape of low-grade serous carcinoma of the ovary

Julian C. Schink, Ruchi Garg, Barbara M. Buttin, Julia Andrea Elvin et autres

Tumor genomic profiling is a critical component of precision oncology allowing the detection of genomic alterations (GA) that are potential therapeutic targets. We present an analysis of comprehensive genomic profiling (CGP) of a large series of low grade serous ovarian carcinoma patients …

us (code pays fourni par la source)

6 Racial differences in the mutational landscape of serous endometrial cancer

Ruchi Garg, Julian C. Schink, Barbara M. Buttin, Julia Andrea Elvin et autres

Tumor comprehensive genomic profiling (CGP) identifying genomic alterations (GA) that have diagnostic, prognostic and are potentially therapeutically targetable is essential to precision oncology. 2022 NCCN Uterine Neoplasm guidelines recommend tumor genetic evaluation as part of initial evaluation. As racial disparities in endometrial …

us (code pays fourni par la source)

Racial differences in the mutational landscape of serous endometrial cancer.

Julian C. Schink, Ruchi Garg, Barbara M. Buttin, Julia Andrea Elvin et autres

5600 Background: Tumor comprehensive genomic profiling (CGP) identifying genomic alterations (GA) that have diagnostic, prognostic and are potentially therapeutically targetable is essential to precision oncology. 2022 NCCN Uterine Neoplasm guidelines recommend tumor genetic evaluation as part of initial evaluation. As racial disparities …

us (code pays fourni par la source)

Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race.

Ruchi Garg, Julian C. Schink, Barbara M. Buttin, Julia Andrea Elvin et autres

e17590 Background: Individualizing oncologic treatment by using precision oncology techniques that allow for detection of genomic alterations (GA) has become critical. We present an analysis of comprehensive genomic profiling (CGP) of a large series of high grade serous ovarian carcinoma (HGSOC) patients …

us (code pays fourni par la source)

Mutational landscape of low-grade serous carcinoma of the ovary.

Julian C. Schink, Ruchi Garg, Julia Andrea Elvin, Natalie Godbee et autres

5578 Background: Tumor genomic profiling is a critical component of precision oncology allowing the detection of genomic alterations (GA) that are potential therapeutic targets. We present an analysis of comprehensive genomic profiling (CGP) of a large series of low grade serous ovarian …

us (code pays fourni par la source)

Mutational landscape of gynecologic cancers identified by prospective clinical sequencing in a nationwide cancer network

Julian C. Schink, Ricardo H. Álvarez, Julia Andrea Elvin, Amber Moran et autres

us (code pays fourni par la source)

Mutational landscape of cervical cancer identified by prospective clinical sequencing in a nationwide cancer network.

Julian C. Schink, Ricardo H. Álvarez, Julia Andrea Elvin, Amber Moran et autres

e17022 Background: Tumor genomic profiling is a critical component of precision oncology allowing the detection of genomic alterations (GA) that have the potential to be targeted therapeutically. We present an analysis of comprehensive genomic profiling (CGP) of a large series of cervical …

us (code pays fourni par la source)

Mutational landscape of endometrial cancer identified by prospective clinical sequencing in a nationwide cancer network.

Julian C. Schink, Ricardo H. Álvarez, Julia Andrea Elvin, Amber Moran et autres

e17123 Background: Tumor genomic profiling is a critical component of precision oncology allowing the detection of genomic alterations (GA) that have the potential to be targeted therapeutically. We present an analysis of comprehensive genomic profiling (CGP) of a large series of endometrial …

us (code pays fourni par la source)